Stockreport

EXCLUSIVE: Gain Therapeutics Highlights Lead Program Data Showcasing Its Impact On Cellular Death For Treating Parkinson's Disease [Yahoo! Finance]

Gain Therapeutics, Inc.  (GANX) 
PDF and related neurological disorders (AD/PD 2024) related to the mechanism of action of the company's lead compound, GT-02287. The poster demonstrates how GT-02287, thro [Read more]